Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic

INTRODUCTION: Extended interval (EI) dosing for immune checkpoint inhibitor (ICI) mono- or consolidation therapy initiated due to the COVID-19 pandemic led to a significant reduction in ICI-related site visits for patients with stage III and IV non–small cell lung cancer. Here we report the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijmering-Kappelle, L.B.M., Hiltermann, T.J.N, Bensch, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc. 2022
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704727/
https://www.ncbi.nlm.nih.gov/pubmed/35034861
http://dx.doi.org/10.1016/j.cllc.2021.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704727/
https://www.ncbi.nlm.nih.gov/pubmed/35034861
http://dx.doi.org/10.1016/j.cllc.2021.12.005

Ejemplares similares